Literature DB >> 21170610

Hypocretin and its emerging role as a target for treatment of sleep disorders.

Michelle Cao1, Christian Guilleminault.   

Abstract

The neuropeptides hypocretin-1 and -2 (orexin A and B) are critical in the regulation of arousal and maintenance of wakefulness. Understanding the role of the hypocretin system in sleep/wake regulation has come from narcolepsy-cataplexy research. Deficiency of hypocretin results in loss of sleep/wake control with consequent unstable transitions from wakefulness into non-rapid eye movement (REM) and REM sleep, and clinical manifestations including daytime hypersomnolence, sleep attacks, and cataplexy. The hypocretin system regulates sleep/wake control through complex interactions between monoaminergic/cholinergic wake-promoting and GABAergic sleep-promoting neuronal systems. Research for the hypocretin agonist and the hypocretin antagonist for the treatment of sleep disorders has vigorously increased over the past 10 years. This review will focus on the origin, functions, and mechanisms in which the hypocretin system regulates sleep and wakefulness, and discuss its emerging role as a target for the treatment of sleep disorders.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21170610     DOI: 10.1007/s11910-010-0172-9

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  47 in total

1.  Effects of lateral preoptic area application of orexin-A on sleep-wakefulness.

Authors:  M M Methippara; M N Alam; R Szymusiak; D McGinty
Journal:  Neuroreport       Date:  2000-11-09       Impact factor: 1.837

2.  Orexin receptor antagonism, a new sleep-promoting paradigm: an ascending single-dose study with almorexant.

Authors:  P Hoever; S de Haas; J Winkler; R C Schoemaker; E Chiossi; J van Gerven; J Dingemanse
Journal:  Clin Pharmacol Ther       Date:  2010-04-07       Impact factor: 6.875

3.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

4.  Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity.

Authors:  J Hara; C T Beuckmann; T Nambu; J T Willie; R M Chemelli; C M Sinton; F Sugiyama; K Yagami; K Goto; M Yanagisawa; T Sakurai
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

5.  Discovery of the dual orexin receptor antagonist [(7R)-4-(5-chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-triazol-2-yl)phenyl]methanone (MK-4305) for the treatment of insomnia.

Authors:  Christopher D Cox; Michael J Breslin; David B Whitman; John D Schreier; Georgia B McGaughey; Michael J Bogusky; Anthony J Roecker; Swati P Mercer; Rodney A Bednar; Wei Lemaire; Joseph G Bruno; Duane R Reiss; C Meacham Harrell; Kathy L Murphy; Susan L Garson; Scott M Doran; Thomayant Prueksaritanont; Wayne B Anderson; Cuyue Tang; Shane Roller; Tamara D Cabalu; Donghui Cui; George D Hartman; Steven D Young; Ken S Koblan; Christopher J Winrow; John J Renger; Paul J Coleman
Journal:  J Med Chem       Date:  2010-07-22       Impact factor: 7.446

6.  Sleep-waking discharge of neurons in the posterior lateral hypothalamus of the albino rat.

Authors:  T L Steininger; M N Alam; H Gong; R Szymusiak; D McGinty
Journal:  Brain Res       Date:  1999-09-04       Impact factor: 3.252

7.  Sleep-waking discharge patterns of ventrolateral preoptic/anterior hypothalamic neurons in rats.

Authors:  R Szymusiak; N Alam; T L Steininger; D McGinty
Journal:  Brain Res       Date:  1998-08-24       Impact factor: 3.252

8.  Hypothalamic orexin neurons regulate arousal according to energy balance in mice.

Authors:  Akihiro Yamanaka; Carsten T Beuckmann; Jon T Willie; Junko Hara; Natsuko Tsujino; Michihiro Mieda; Makoto Tominaga; Ken ichi Yagami; Fumihiro Sugiyama; Katsutoshi Goto; Masashi Yanagisawa; Takeshi Sakurai
Journal:  Neuron       Date:  2003-06-05       Impact factor: 17.173

9.  Intranasal drug targeting of hypocretin-1 (orexin-A) to the central nervous system.

Authors:  Shyeilla V Dhuria; Leah R Hanson; William H Frey
Journal:  J Pharm Sci       Date:  2009-07       Impact factor: 3.534

10.  IGFBP3 colocalizes with and regulates hypocretin (orexin).

Authors:  Makoto Honda; Krister S Eriksson; Shengwen Zhang; Susumu Tanaka; Ling Lin; Ahmad Salehi; Per Egil Hesla; Jan Maehlen; Stephanie E Gaus; Masashi Yanagisawa; Takeshi Sakurai; Shahrad Taheri; Kuniaki Tsuchiya; Yutaka Honda; Emmanuel Mignot
Journal:  PLoS One       Date:  2009-01-22       Impact factor: 3.240

View more
  12 in total

Review 1.  The Neurobiological Basis of Sleep and Sleep Disorders.

Authors:  William J Joiner
Journal:  Physiology (Bethesda)       Date:  2018-09-01

2.  Hypocretin Mediates Sleep and Wake Disturbances in a Mouse Model of Traumatic Brain Injury.

Authors:  Hannah E Thomasy; Mark R Opp
Journal:  J Neurotrauma       Date:  2018-10-03       Impact factor: 5.269

3.  Neurogenesis-independent antidepressant-like effects on behavior and stress axis response of a dual orexin receptor antagonist in a rodent model of depression.

Authors:  Mathieu Nollet; Philippe Gaillard; Arnaud Tanti; Virginie Girault; Catherine Belzung; Samuel Leman
Journal:  Neuropsychopharmacology       Date:  2012-06-20       Impact factor: 7.853

Review 4.  Sleep disorders, obesity, and aging: the role of orexin.

Authors:  Joshua P Nixon; Vijayakumar Mavanji; Tammy A Butterick; Charles J Billington; Catherine M Kotz; Jennifer A Teske
Journal:  Ageing Res Rev       Date:  2014-11-22       Impact factor: 10.895

5.  Expression of orexin A and its receptor 1 in the human prostate.

Authors:  Salvatore Valiante; Giovanna Liguori; Simona Tafuri; Roberto Campese; Roberto Monaco; Salvatore Paino; Vincenza Laforgia; Norma Staiano; Alfredo Vittoria
Journal:  J Anat       Date:  2013-02-21       Impact factor: 2.610

6.  Almorexant promotes sleep and exacerbates cataplexy in a murine model of narcolepsy.

Authors:  Sarah Wurts Black; Stephen R Morairty; Simon P Fisher; Tsui-Ming Chen; Deepti R Warrier; Thomas S Kilduff
Journal:  Sleep       Date:  2013-03-01       Impact factor: 5.849

7.  Hypocretin/orexin prevents recovery from sickness.

Authors:  Susumu Tanaka; Hiromi Toyoda; Yoshiko Honda; Yasuko Seki; Takeshi Sakurai; Kazuki Honda; Tohru Kodama
Journal:  Biomed Rep       Date:  2015-07-17

8.  Absence of pharmacokinetic and pharmacodynamic interactions between almorexant and warfarin in healthy subjects.

Authors:  Jasper Dingemanse; Petra Hoever
Journal:  Drugs R D       Date:  2013-06

9.  Dual orexin receptor antagonists increase sleep and cataplexy in wild type mice.

Authors:  Carrie E Mahoney; Takatoshi Mochizuki; Thomas E Scammell
Journal:  Sleep       Date:  2020-06-15       Impact factor: 5.849

10.  Innervation of ventricular and periventricular brain compartments.

Authors:  Rehana K Leak; Robert Y Moore
Journal:  Brain Res       Date:  2012-05-07       Impact factor: 3.252

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.